

DEEPAK L. BHATT, MD*

Associate Director, Cardiovascular Coordinating Center, and Staff, Cardiac, Peripheral, and Carotid Intervention, Department of Cardiovascular Medicine, Cleveland Clinic; Associate Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

INTERPRETING THE COURAGE TRIAL

Is medical therapy as good as PCI in stable angina? Two views

IN A LANDMARK STUDY, the Clinical Outcomes Utilizing Percutaneous Coronary Revascularization and Aggressive Drug Evaluation (COURAGE)¹ compared two initial treatment strategies for patients with stable angina: percutaneous coronary revascularization plus optimal medical therapy vs optimal medical therapy alone.

The study found no significant difference in the incidence of death or myocardial infarction (MI) with either strategy, though angina was modestly reduced with the strategy that included initial revascularization. The patients treated with medical therapy alone fared surprisingly well, though about one-third went on to require revascularization.

See related “point” article by Dr. William Boden on page 623 and “counterpoint” article by Dr. Dean Kereiakes on page 637

The study received a great deal of media attention,² and patients are asking how the results should affect treatment decisions in their own care. COURAGE has the potential to influence practice, particularly in the United States, where revascularization for stable angina is much more common as the initial treatment than it is in other parts of the world.

In this issue of the *Cleveland Clinic Journal of Medicine*, we are fortunate to have a “point-counterpoint” between the principal investi-

gator of the COURAGE trial, Dr. William Boden, and a leading interventional cardiologist, Dr. Dean Kereiakes. In addition to being prominent academicians, both are in charge of cardiovascular services in their respective health care systems. The possible ramifications of the results extend beyond the clinical and scientific to issues such as the impact on procedural volume and reimbursement—thorny issues that both these physicians will need to face in their leadership positions.

■ WHAT COURAGE WAS NOT, AND WHAT IT WAS

It is important to realize what the trial was not. COURAGE did not examine patients with unstable ischemic syndromes. The role of primary percutaneous coronary intervention in ST-segment elevation MI for reducing subsequent death or reinfarction is established.³ Similarly, in non-ST-segment-elevation MI and high-risk unstable angina, both percutaneous and surgical revascularization appear to reduce the incidence of death, MI, and the need for subsequent procedures.^{4,5} In fact, a meta-analysis in which Dr. Boden was one of the coauthors supports this observation.^{6,7}

In stable angina, however, the COURAGE results suggest that many patients are served well by a strategy of medical therapy first, even though many doctors and especially patients believe that stents (or bypass grafts) should prevent death and MI in this disease.

Although nearly all of the stents used in COURAGE were bare-metal stents (as drug-eluting stents were not yet widely available),

Like any trial, COURAGE has nuances in how it should be interpreted and applied

*Dr. Bhatt has disclosed that he has received grants, research support, or honoraria from Astra Zeneca, Bristol Myers Squibb, Cardax, Centocor, Cogentus, Daiichi-Sankyo, Eisai, Eli Lilly, Ethicon, Glaxo Smith Kline, Johnson and Johnson, McNeill, Medtronic, Millennium, Otsuka, Paringenix, PDL, Sanofi Aventis, Schering Plough, The Medicines Company, tns Healthcare, and Vertex; he currently donates all honoraria to nonprofit organizations.

We Welcome Your Letters

WE ENCOURAGE YOU TO WRITE, either to respond to an article published in the *Journal* or to address a clinical issue of importance to you. You may submit letters by mail, fax, or e-mail.

Please be sure to include your full address, phone number, fax number, and e-mail address. Please write concisely, as space is limited. Letters may be edited for style and length. We cannot return materials sent. Submission of a letter constitutes permission for the *Cleveland Clinic Journal of Medicine* to publish it in various editions and forms.

MAILING ADDRESS

Letters to the Editor
Cleveland Clinic Journal of Medicine
9500 Euclid Ave., NA32
Cleveland, OH 44195
FAX 216.444.9385
E-MAIL ccjm@ccf.org



CME ANSWERS

Answers to the credit test on page 687 of this issue
1 D 2 B 3 C 4 D 5 A 6 B 7 F 8 D 9 D 10 E 11 B 12 B

STABLE ANGINA

BHATT

it is not clear that drug-eluting stents would change the equation with respect to death or MI rates, though they might have been expected to further decrease angina and the need for repeat revascularization.⁸⁻¹⁰

Stable patients at higher risk than those enrolled in COURAGE, including those with silent ischemia, may indeed manifest a reduction in cardiovascular mortality rates with percutaneous coronary intervention on long-term follow-up, as a recent study of patients with prior MI demonstrated.¹¹

Like any clinical trial, COURAGE has nuances in how its results should be interpreted and applied to actual clinical practice, and Drs. Boden and Kereiakes provide great insight in the following point-counterpoint. ■

REFERENCES

1. **Boden WE, O'Rourke RA, Teo KK, et al; COURAGE Trial Research Group.** Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med* 2007; 356:1503-1516.
2. **Feder BJ.** Test results due out soon are crucial to stents' future. *New York Times*, March 24, 2007.
3. **Keeley EC, Boura JA, Grines CL.** Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. *Lancet* 2003; 361:13-20.
4. **Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT.** Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. *J Am Coll Cardiol* 2006; 48:1319-1325.
5. **Shishebor MH, Lauer MS, Singh IM, et al.** In unstable angina or non-ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting? *J Am Coll Cardiol* 2007; 49:849-854.
6. **Mehta SR, Cannon CP, Fox KA, et al.** Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. *JAMA* 2005; 293:2908-2917.
7. **Bhatt DL.** To cath or not to cath: that is no longer the question. *JAMA* 2005; 293:2935-2937.
8. **Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL.** Bare metal stent restenosis is not a benign clinical entity. *Am Heart J* 2006; 151:1260-1264.
9. **Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL.** Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. *Am J Med* 2006; 119:1056-1061.
10. **Rabbat MG, Bavry AA, Bhatt DL, Ellis SG.** Understanding and minimizing late thrombosis of drug-eluting stents. *Cleve Clin J Med* 2007; 74:129-136.
11. **Erne P, Schoenenberger AW, Burckhardt D, et al.** Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. *JAMA* 2007; 297:1985-1991.

ADDRESS: Deepak L. Bhatt, MD, Department of Cardiovascular Medicine, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail bhatted@ccf.org.